Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

[1]  J. Andersen,et al.  An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics , 2020, Science Translational Medicine.

[2]  K. Howard,et al.  Albumin-based drug designs for pharmacokinetic modulation , 2020, Expert opinion on drug metabolism & toxicology.

[3]  T. Sulea,et al.  Serum albumin‐binding VHHs with variable pH sensitivities enable tailored half‐life extension of biologics , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  K. D. Sørensen,et al.  FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  D. Irvine,et al.  Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor , 2019, Science.

[7]  P. Parren,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[8]  T. Arndt.  Crystal , 2019, Springer Reference Medizin.

[9]  J. Cameron,et al.  Cellular recycling‐driven in vivo half‐life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  L. Álvarez-Vallina,et al.  Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies , 2018, Cancer Immunology, Immunotherapy.

[11]  J. Andersen,et al.  A human endothelial cell-based recycling assay for screening of FcRn targeted molecules , 2018, Nature Communications.

[12]  E. M. Cook,et al.  Potent and Selective Antitumor Activity of a T-Cell Engaging Bispecific Antibody Targeting a Membrane-Proximal Epitope of ROR1 , 2017, bioRxiv.

[13]  J. Cameron,et al.  Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin , 2017, The Journal of Biological Chemistry.

[14]  P. Chevallier,et al.  Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Thomas D. Wu,et al.  Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.

[16]  J. O’Shaughnessy,et al.  Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study , 2016, Breast cancer.

[17]  C. Klein,et al.  Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. , 2016, Protein engineering, design & selection : PEDS.

[18]  M. Ebinger,et al.  T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts , 2016, Oncotarget.

[19]  Leslie R Evans,et al.  Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[20]  W. Hiddemann,et al.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.

[21]  Alexandria P. Cogdill,et al.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.

[22]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[23]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[24]  Magnar Bjørås,et al.  Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding* , 2014, The Journal of Biological Chemistry.

[25]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[26]  Gary L Gilliland,et al.  An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. , 2014, Methods.

[27]  Michael M. Schmidt,et al.  Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. , 2013, Structure.

[28]  R. Roovers,et al.  Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. , 2013, Structure.

[29]  J. Andersen,et al.  Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner , 2013, The Journal of Biological Chemistry.

[30]  J. Andersen,et al.  Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor , 2012, Nature Communications.

[31]  J. Andersen,et al.  Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.

[32]  M. Friedrich,et al.  T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.

[33]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[34]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[35]  C. R. Leemans,et al.  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.

[36]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[37]  R. Kontermann,et al.  Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.

[38]  S. Ross,et al.  Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. , 2007, Cancer research.

[39]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[41]  T. Peters,et al.  All About Albumin: Biochemistry, Genetics, and Medical Applications , 1995 .

[42]  C. Ferran,et al.  IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.

[43]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.